Cysteine

Generic Name: Cysteine

Brand Names: Elcys, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Nouress, Premasol, Primene, Procalamine 3, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₃H_₇NO_₂S

CAS Number: 52-90-4

Unique Ingredient Identifier: K848JZ4886

Background: A thiol-containing non-essential amino acid that is oxidized to form cystine.

Indication: For the prevention of liver damage and kidney damage associated with overdoses of acetaminophen

Associated Therapies: Total parenteral nutrition therapy, Amino acid supplementation

Clinical Trials

the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

Phase 2

Recruiting

Conditions: Drug Resistant Epilepsy

Interventions: Drug: N-acetyl cysteine
Drug: Placebo
Drug: NAc

First Posted Date: 2022-08-03

Last Posted Date: 2023-05-23

Lead Sponsor: Tanta University

Target Recruit Count: 45

Registration Number: NCT05485558

Locations: 🇪🇬
Tanta University, Tanta, Egypt

NAC Effect on Infertile Women With Endometrioma

Phase 3

Conditions: Female Infertility
Endometrioma
Stress Oxidative

Interventions: Drug: placebo
Drug: N-acetyl cysteine

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-15

Lead Sponsor: Royan Institute

Target Recruit Count: 140

Registration Number: NCT05460858

Locations: 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

Phase 4

Recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: N-acetyl cysteine
Drug: Placebo

First Posted Date: 2022-06-07

Last Posted Date: 2023-03-16

Lead Sponsor: University of Sydney

Target Recruit Count: 280

Registration Number: NCT05408247

Locations: 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺
Cornwall Street Medical Centre (UQ Health Care), Annerley, Queensland, Australia
🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity

Not Applicable

Not yet recruiting

Conditions: Myocardial Injury

Interventions: Drug: N-acetyl cysteine

First Posted Date: 2022-05-11

Last Posted Date: 2022-05-11

Lead Sponsor: Assiut University

Target Recruit Count: 58

Registration Number: NCT05370729

Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

Phase 2

Completed

Conditions: Bipolar I Disorder
Bipolar II Disorder
Bipolar Disorder

Interventions: Drug: N-Acetyl cysteine
Drug: Placebo

First Posted Date: 2022-04-22

Last Posted Date: 2024-06-26

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 12

Registration Number: NCT05340504

Locations: 🇺🇸
Medical University Of South Carolina, Charleston, South Carolina, United States

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

Early Phase 1

Completed

Conditions: Skin Disorder
Pruritus

Interventions: Drug: N-acetyl cysteine
Drug: Placebo

First Posted Date: 2022-03-18

Last Posted Date: 2024-03-06

Lead Sponsor: Wright State University

Target Recruit Count: 20

Registration Number: NCT05287724

Locations: 🇺🇸
Wright State Physicians, Fairborn, Ohio, United States

Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3

Not Applicable

Completed

Conditions: Contrast-induced Nephropathy
Chronic Kidney Disease stage3

Interventions: Drug: Isotonic saline
Drug: N-acetyl cysteine
Drug: Febuxostat 80 MG

First Posted Date: 2022-03-03

Last Posted Date: 2022-03-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT05264584

Locations: 🇪🇬
Ain shams university hospitals, Cairo, Egypt

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Phase 2

Recruiting

Conditions: Multiple Sclerosis
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive

Interventions: Drug: N-acetyl cysteine
Drug: Placebo

First Posted Date: 2021-11-16

Last Posted Date: 2024-05-07

Lead Sponsor: Emmanuelle Waubant, MD PhD

Target Recruit Count: 98

Registration Number: NCT05122559

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Intravenous NAC Use in ACLF Patients

Not Applicable

Conditions: Acute on Chronic Liver Failure(ACLF)

Interventions: Drug: N acetyl cysteine
Drug: Placebo of N acetyl cysteine

First Posted Date: 2021-10-22

Last Posted Date: 2021-10-22

Lead Sponsor: Aga Khan University

Target Recruit Count: 100

Registration Number: NCT05089981

Locations: 🇵🇰
Aga Khan University,, Karachi, Sind, Pakistan

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

Early Phase 1

Recruiting

Conditions: Gulf War Syndrome

Interventions: Drug: N-Acetyl Cysteine
Drug: Placebo

First Posted Date: 2021-08-03

Last Posted Date: 2024-10-14

Lead Sponsor: Nova Southeastern University

Target Recruit Count: 170

Registration Number: NCT04987775

Locations: 🇺🇸
VA New Jersey Health Care System War Related Illness and Injury Study Center, East Orange, New Jersey, United States
🇺🇸
RTI International, Durham, North Carolina, United States
🇺🇸
VA Palo Alto Health Care System War Related Illness and Injury Study Center, Palo Alto, California, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy